KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Receivables - Net: 2018-2025

Historic Receivables - Net for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $49.5 million.

  • Castle Biosciences' Receivables - Net fell 1.55% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year decrease of 1.55%. This contributed to the annual value of $51.2 million for FY2024, which is 33.72% up from last year.
  • Castle Biosciences' Receivables - Net amounted to $49.5 million in Q3 2025, which was down 5.41% from $52.3 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Receivables - Net peaked at $56.4 million during Q1 2025, and registered a low of $14.3 million during Q1 2021.
  • Its 3-year average for Receivables - Net is $43.9 million, with a median of $46.0 million in 2024.
  • Its Receivables - Net has fluctuated over the past 5 years, first decreased by 2.11% in 2021, then surged by 63.15% in 2023.
  • Quarterly analysis of 5 years shows Castle Biosciences' Receivables - Net stood at $17.3 million in 2021, then surged by 35.84% to $23.5 million in 2022, then surged by 63.15% to $38.3 million in 2023, then soared by 33.72% to $51.2 million in 2024, then declined by 1.55% to $49.5 million in 2025.
  • Its Receivables - Net stands at $49.5 million for Q3 2025, versus $52.3 million for Q2 2025 and $56.4 million for Q1 2025.